Opendata, web and dolomites

TISSUE

Tissue In Stroke Stratification Using e-ASPECTSTW

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TISSUE project word cloud

Explore the words cloud of the TISSUE project. It provides you a very rough idea of what is the project "TISSUE" about.

standardised    position    prospective    feasibility    acute    full    325    version    validate    25    approved    aspectstw    medical    strategy    size    trial    pricing    projections    annual    arrive    health    cerebrovascular    brain    nccts    contrast    hospitals    worldwide    benefit    receive    stratification    275    model    neurological    additional    treatment    financial    hours    accessible    software    computed    clinically    250    stroke    business    indirect    intravenous    tissue    reaching    biomarker    output    commercial    restricted    global    000    centre    economic    patients    employment    ncct    clinical    disorders    leaders    symptom    brainomix    burden    automated    fast    scans    market    tomography    device    budget    ischaemic    easily    units    direct    competition    onset    revenues    eligible    biomarkers    untreated    imaging    socioeconomic    hospital    benefits    profits    ltd    participating    thrombolysis    time    euros    20    unknown    plan   

Project "TISSUE" data sheet

The following table provides information about the project.

Coordinator
BRAINOMIX LIMITED 

Organization address
address: SUFFOLK HOUSE SUITES 11-14 263 BANBURY ROAD
city: OXFORD
postcode: OX2 7HN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2594-phc-12-2014.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2014
 Duration (year-month-day) from 2014-10-01   to  2015-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BRAINOMIX LIMITED UK (OXFORD) coordinator 50˙000.00

Map

 Project objective

Stroke is a burden with far reaching socioeconomic impact. The only approved treatment in ischaemic stroke is intravenous thrombolysis, which is restricted to 4.5 hours after symptom onset and currently, only 20% of all stroke cases are eligible to receive it. An additional 25% remain untreated because they arrive at the hospital with unknown time of onset.

The objective of the “Tissue In Stroke Stratification Using e-ASPECTSTW” (TISSUE) proposal is to clinically validate the ASPECTS method and its automated version, the medical device software e-ASPECTSTW, as an imaging biomarker on Non-Contrast Computed Tomography (NCCT) brain scans for identifying ischaemic stroke patients with unknown time of onset who can benefit from thrombolysis.

e-ASPECTSTW addresses the growing worldwide market of 3,250,000 patients (275,000 patients in Europe) every year having a stroke with unknown time of onset. The annual global market size of e-ASPECTSTW is 325,000,000 Euros. Users of e-ASPECTSTW will be hospitals worldwide that provide acute stroke treatment. e-ASPECTSTW will be integrated in existing clinical pathways offering a standardised, fast, reliable and easily accessible assessment of NCCTs. This will increase the uptake of thrombolysis and provide significant economic benefits to hospitals and the health system. The commercial exploitation of the project results will enhance the growth of Brainomix Ltd leading to increased revenues, profits, employment and will position Brainomix as leaders in imaging biomarkers for neurological and cerebrovascular disorders.

The output of the feasibility study will be a full business plan, including an analysis of the European and global stroke market, an analysis of direct, indirect and potential competition; a detailed business model and pricing strategy as well as financial projections and a detailed design and budget of the prospective multi-centre clinical trial including the participating stroke units.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TISSUE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TISSUE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More